Antibodies created due to influenza (flu) vaccinations develop in the body two weeks after immunization. These antibodies protect against infection from viruses that are used to produce a vaccine. According to a study, the seasonal flu vaccine protects against influenza viruses that are predicted to be the most common over the coming season.

RNA vaccines can be administered by a variety of routes, including needle syringe injections into the skin, directly into bloodstream, lymph, and organs; it can even be administered via nasal spray.  RNA-based vaccines are generally relatively quick and affordable to manufacture, they may be safer to administer and may herald a more rapid control of infectious diseases including influenza, COVID-19, etc.

The main benefit of RNA vaccines is that they do not require the use of live cells in the vaccine preparation process. Instead, these vaccines can be manufactured in the lab using a DNA template with readily available materials, making them a simple and quick weapon to combat new outbreaks and existing infectious diseases.

Detailed Segmentation –

The global flu RNA vaccines market is segmented on the basis of – Product Types, Route of Administration, Age Group, Distribution Channels, and Region. Represented below is a detailed segmental description:

Based on Product Types:

• Non-replicating mRNA
• In vivo self-replicating mRNA
• In Vitro Dendritic Cell Non-replicating mRNA Vaccine

Based on Route of Administration:

• Injections
• Nasal Sprays

Based on Age Group:

• Pediatrics
• Adults

Based on Distribution Channels:

• Hospitals
• Vaccination Centers
• Specialized Clinics
• Hospital Pharmacies

Based on Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Market Dynamics –

Drivers for the Global Flu RNA Vaccines Market:

RNA vaccines have a number of advantages, including a simple production procedure that allows them to be manufactured faster than other vaccinations. In this pandemic, RNA vaccines can be prepared in about eight days. Even if flu virus strains change from year-to-year, the manufacturing method remains the same. This factor is expected to boost the economic growth of this market.

During the COVID-19 pandemic, this market increased at an astonishing rate because of the augmented demand for flu vaccines across all locations that were impacted by this pandemic. As a result, the COVID-19 pandemic has had a favorable impact on this market.

Opportunities for the Global Flu RNA Vaccines Market:

Existing industry players are focusing on innovation and finding efficient Flu RNA vaccines, as well as missing elements in technologies that may help to manufacture these vaccines at a more rapid pace. These factors are expected to create lucrative opportunities for this market.

 Competitive Landscape –

Key players in this market are –  Sanofi Pasteur Inc. (Sanofi S/A), AstraZeneca Plc, CSL Ltd. (Seqirus), Abbott Laboratories, GlaxoSmithKline Plc, Serum Institute of India Pvt. Ltd., Pfizer Inc., BioNTech SE, F. Hoffman La Roche Ltd., Novartis International AG, Sinnovac Biotech Ltd., Moderna Inc., and CureVac N.V., among others. These key industry players are now focusing on mergers, partnerships, acquisitions, product developments, and collaboration strategies, in order to sustain their respective competitive edges.

Key Developments –

• Pfizer has recently entered into a collaboration with German biotech company BioNTech to develop new RNA vaccine technology to create a better flu shot.

---

For the Flu RNA Vaccines Market research study, the following years have been considered to estimate the market size: